The Covid-19 pandemic has left pharmaceutical companies, particularly those in the psychiatry space, contending to learn the disaster’s impact on patient-reported outcomes (PROs) utilised in studies and similar subjective measures that calculate patient or caregiver emotions.
To salvage PROs, as well as other results for studies in any therapeutic area that started before the beginning of the pandemic, clients are advised to translate data collected pre-, during and post-Covid-19, as well as conduct sensitivity analysis. Read more here.
Go deeper with GlobalData
